Fitness trade-offs in blaTEM evolution

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 7, 2008, Pages 2340-2345

  Mroczkowska, Joanna E ^a   Barlow, Miriam ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAMASE TEM 1; CEFTAZIDIME; EXTENDED SPECTRUM BETA LACTAMASE; PENICILLIN DERIVATIVE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BACTERIAL STRAIN; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; AMINO ACID SUBSTITUTION; AMPICILLIN RESISTANCE; BASE SEQUENCE; BETA-LACTAMASES; DNA PRIMERS; DNA, BACTERIAL; ESCHERICHIA COLI; EVOLUTION, MOLECULAR; GENES, BACTERIAL; HUMANS; MUTAGENESIS, SITE-DIRECTED; UNITED STATES;

EID: 46249099127     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00018-08     Document Type: Article

References (34)

1. Baraniak, A., J. Fiett, A. Mrowka, J. Walory, W. Hryniewicz, and M. Gniadkowski. 2005. Evolution of TEM-type extended-spectrum beta-lactamases in clinical Enterobacteriaceae strains in Poland. Antimicroh. Agents Chemother. 49:1872-1880.
2. Blazquez, J., M. C. Negri, M. I. Morosini, J. M. Gomez-Gomez, and F. Baquero. 1998. A237T as a modulating mutation in naturally occurring extended-spectrum TEM-type heta-lactamases. Antimicrob. Agents Chemother. 42:1042-1044.
3. Brinas, L., M. Lantero, I. de Diego, M. Alvarez, M. Zarazaga, and C. Torres. 2005. Mechanisms of resistance to expanded-spectrum cephalosporins in Escherichia coli isolates recovered in a Spanish hospital. J. Antimicrob. Chemother. 56:1107-1110.
4. Burman, L. G., J. T. Park, E. B. Lindstrom, and H. G. Boman. 1973. Resistance of Escherichia coli to penicillins: identification of the structural gene for the chromosomal penicillinase. J. Bacteriol. 116:123-130.
5. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. CLSI, Wayne, PA.
6. Coenen, S., M. Ferech, K. Dvorakova, E. Hendrickx, C. Suetens, and H. Goossens. 2006. European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe. J. Antimicrob. Chemother. 58:413-417.
7. Datta, N., and P. Kontomichalou. 1965. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature 208:239-241.
8. Dean, A. M. 1989. Selection and neutrality in lactose operons of Escherichia coli. Genetics 123:441-454.
9. Decre, D., B. Burghoffer, V. Gautier, J. C. Petit, and G. Arlet. 2004. Outbreak of multi-resistant Klebsiella oxytoca involving strains with extended-spectrum beta-lactamases and strains with extended-spectrum activity of the chromosomal beta-lactamase. J. Antimicrob. Chemother. 54:881-888.
10. Ferech, M., S. Coenen, K. Dvorakova, E. Hendrickx, C. Suetens, and H. Goossens. 2006. European Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in Europe. J. Antimicrob. Chemother. 58:408-412.
11. Ferech, M., S. Coenen, S. Malhotra-Kumar, K. Dvorakova, E. Hendrickx, C. Suetens, and H. Goossens. 2006. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J. Antimicrob. Chemother. 58:401-407.
12. Ho, P. L., A. Y. Ho, K. H. Chow, R. C. Wong, R. S. Duan, W. L. Ho, G. C. Mak, K. W. Tsang, W. C. Yam, and K. Y. Yuen. 2005. Occurrence and molecular analysis of extended-spectrum β-lactamase-producing Proteus mirabilis in Hong Kong, 1999-2002. J. Antimicrob. Chemother. 55:840-845.
13. Ho, P. L., R. H. Shek, K. H. Chow, R. S. Duan, G. C. Mak, E. L. Lai, W. C. Yam, K. W. Tsang, and W. M. Lai. 2005. Detection and characterization of extended-spectrum beta-lactamases among bloodstream isolates of Enterobacter spp. in Hong Kong, 2000-2002. J. Antimicrob. Chemother. 55:326-332.
14. IMS Health. 1999. Sales for leading pharmaceutical products. IMS Health, Fairfield, CT.
15. Imtiaz, U., E. K. Manavathu, S. Mobashery, and S. A. Lerner. 1994. Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 beta-lactamase as a result of a second mutation (Arg to Ser at position 164) that enhances activity against ceftazidime. Antimicrob. Agents Chemother. 38:1134-1139.
16. Jaurin, B., T. Grundstrom, T. Edlund, and S. Normark. 1981. The E. coli beta-lactamase attenuator mediates growth rate-dependent regulation. Nature 290:221-225.
17. Kim, S., J. Kim, Y. Kang, Y. Park, and B. Lee. 2004. Occurrence of extended-spectrum beta-lactamases in members of the genus Shigella in the Republic of Korea. J. Clin. Microbiol. 42:5264-5269.
18. Knox, J. R. 1995. Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob. Agents Chemother. 39:2593-2601.
19. Kruger, T., D. Szabo, K. H. Keddy, K. Deeley, J. W. Marsh, A. M. Hujer, R. A. Bonomo, and D. L. Paterson. 2004. Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. Antimicrob. Agents Chemother. 48:4263-4270.
20. Lavigne, J. P., N. Bouziges, C. Chanal, A. Mahamat, S. Michaux-Charachon, and A. Sotto. 2004. Molecular epidemiology of Enterobacteriaceae isolates producing extended-spectrum beta-lactamases in a French hospital. J. Clin. Microbiol. 42:3805-3808.
21. Livermore, D. M. 1996. Are all beta-lactams created equal? Scand. J. Infect. Dis. Suppl. 101:33-43.
22. Matagne, A., and J. M. Frere. 1995. Contribution of mutant analysis to the understanding of enzyme catalysis: the case of class A heta-lactamases. Biochim. Biophys. Acta 1246:109-127.
23. Medeiros, A. A. 1997. Evolution and dissemination of beta-lactamases accelerated hy generations of beta-lactam antibiotics. Clin. Infect. Dis. 24:S19-S45.
24. NDCHealth. 2002. NDCHealth pharmaceutical audit suite prescription monthly for 2001. NDCHealth, Atlanta, GA.
25. NDCHealth. 2003. NDCHealth pharmaceutical audit suite prescription monthly for 2002. NDCHealth, Atlanta, GA.
26. NDCHealth. 2004. NDCHealth pharmaceutical audit suite prescription monthly for 2003. NDCHealth, Atlanta, GA.
27. NDCHealth. 2005. NDCHealth pharmaceutical audit suite prescription monthly for 2004. NDCHealth, Atlanta, GA.
28. Paterson, D. L., and R. A. Bonomo. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
29. Queenan, A. M., B. Foleno, C. Gownley, E. Wira, and K. Bush. 2004. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J. Clin. Microbiol. 42:269-275.
30. Schlesinger, J., S. Navon-Venezia, I. Chmelnitsky, O. Hammer-Munz, A. Leavitt, H. S. Gold, M. J. Schwaber, and Y. Carmeli. 2005. Extended-spectrum beta-lactamases among Enterobacter isolates obtained in Tel Aviv, Israel. Antimicrob. Agents Chemother. 49:1150-1156.
31. Scott-Levin. 2001. Physician drug and diagnososis audit for 2000. ScottLevin, Newton, PA. http://www.rxlist.com/top200.htm.
32. Sirot, D., J. Sirot, R. Labia, A. Morand, P. Courvalin, A. Darfeuille-Michaud, R. Perroux, and R. Cluzel. 1987. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase. J. Antimicrob. Chemother. 20:323-334.
33. Sowek, J. A., S. B. Singer, S. Ohringer, M. F. Malley, T. J. Dougherty, J. Z. Gougoutas, and K. Bush. 1991. Substitution of lysine at position 104 or 240 of TEM-1pTZ18R beta-lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam. Biochemistry 30:3179-3188.
34. Tasli, H., and I. H. Bahar. 2005. Molecular characterization of TEM- and SHV-derived extended-spectrum beta-lactamases in hospital-based Enterobacteriaceae in Turkey. Jpn. J. Infect. Dis. 58:162-167.